Erratum: Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial (The Lancet (2016) 388(10054) (1883–1892) (S0140673616313885) (10.1016/S0140-6736(16)31388-5));Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

The Lancet

Volumn 388, Issue 10054, 2016, Pages 1883-1892

  Zhang, Li ^a   Huang, Yan ^a   Hong, Shaodong ^a   Yang, Yunpeng ^a   Yu, Gengsheng ^b   Jia, Jun ^c   Peng, Peijian ^d   Wu, Xuan ^a   Lin, Qing ^e   Xi, Xuping ^f   Peng, Jiewen ^g   Xu, Mingjun ^h   Chen, Dongping ⁱ   Lu, Xiaojun ^g   Wang, Rensheng ^j   Cao, Xiaolong ^k   Chen, Xiaozhong ^l   Lin, Zhixiong ^m   Xiong, Jianping ⁿ   Lin, Qin ^o   Xie, Conghua ^p   Li, Zhihua ^q   Pan, Jianji ^r   Li, Jingao ^s   Wu, Shixiu ^l   Lian, Yingni ^t   Yang, Quanlie ^u   Zhao, Chong ^a   more..

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Jiangmen Central Hospital   (China)

^c DONGGUAN PEOPLE'S HOSPITAL   (China)

^d THE FIFTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^e SHUNDE HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^f HUNAN CANCER HOSPITAL   (China)

^g ZHONGSHAN PEOPLE S HOSPITAL   (China)

^h The First Affiliated Hospital of Gangnan Medical College   (China)

ⁱ GUANGZHOU MEDICAL UNIVERSITY   (China)

^j FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^k Panyu Central Hospital   (China)

^l ZHEJIANG CANCER HOSPITAL   (China)

^m CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

ⁿ NANCHANG UNIVERSITY   (China)

^o THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^p ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^q SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^r Fujian Provincial Cancer Hospital   (China)

^s Jiangxi Provincial Cancer Hospital   (China)

^t First People's Hospital of Zhaoqing City   (China)

^u Meizhou People's Hospital   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; DEXAMETHASONE; FLUOROURACIL; FUROSEMIDE; GEMCITABINE; MANNITOL; METOCLOPRAMIDE; PACLITAXEL; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CATHETER ASSOCIATED VENOUS THROMBOSIS; CATHETER INFECTION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTINUOUS INFUSION; CONTROLLED STUDY; DECREASED APPETITE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HYDRATION; HYPONATREMIA; INTENTION TO TREAT ANALYSIS; KIDNEY DYSFUNCTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; VEIN THROMBOSIS; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CANCER STAGING; CHINA; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; ODDS RATIO; PATHOLOGY; PATIENT SELECTION; RISK FACTOR; SECONDARY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; PATIENT SELECTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 84994172995     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31808-6     Document Type: Erratum

References (30)

1. 1 Ferlay, J, Soerjomataram, I, Dikshit, R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. 2 Her, C, Nasopharyngeal cancer and the Southeast Asian patient. Am Fam Physician 63 (2001), 1776–1782.
3. 3 Chua, ML, Wee, JT, Hui, EP, Chan, AT, Nasopharyngeal carcinoma. Lancet 387 (2016), 1012–1024.
4. 4 Blanchard, P, Lee, A, Marguet, S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol 16 (2015), 645–655.
5. 5 Yang, L, Hong, S, Wang, Y, et al. Development and external validation of nomograms for predicting survival in nasopharyngeal carcinoma patients after definitive radiotherapy. Sci Rep, 5, 2015, 15638.
6. 6 Lee, AW, Poon, YF, Foo, W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 23 (1992), 261–270.
7. 7 Li, AC, Xiao, WW, Shen, GZ, et al. Distant metastasis risk and patterns of nasopharyngeal carcinoma in the era of IMRT: long-term results and benefits of chemotherapy. Oncotarget 6 (2015), 24511–24521.
8. 8 Tang, LQ, Chen, QY, Fan, W, et al. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol 31 (2013), 2861–2869.
9. 9 Wei, WI, Sham, JS, Nasopharyngeal carcinoma. Lancet 365 (2005), 2041–2054.
10. 10 Ma, BB, Chan, AT, Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer 103 (2005), 22–31.
11. 11 Lee, AW, Ma, BB, Ng, WT, Chan, AT, Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol 33 (2015), 3356–3364.
12. 12 Jin, Y, Shi, YX, Cai, XY, et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol 138 (2012), 1717–1725.
13. 13 Wang, TL, Tan, YO, Cisplatin and 5-fluorouracil continuous infusion for metastatic nasopharyngeal carcinoma. Ann Acad Med Singapore 20 (1991), 601–603.
14. 14 Choo, R, Tannock, I, Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the Princess Margaret Hospital experience. Cancer 68 (1991), 2120–2124.
15. 15 Bergman, AM, Ruiz van Haperen, VW, Veerman, G, Kuiper, CM, Peters, GJ, Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2 (1996), 521–530.
16. 16 Ma, BB, Tannock, IF, Pond, GR, Edmonds, MR, Siu, LL, Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer 95 (2002), 2516–2523.
17. 17 Wang, J, Li, J, Hong, X, et al. Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma. Oral Oncol 44 (2008), 464–470.
18. 18 Ngan, RK, Yiu, HH, Lau, WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol 13 (2002), 1252–1258.
19. 19 Au, E, Ang, PT, A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol 5 (1994), 87–89.
20. 20 Hsieh, JC, Hsu, CL, Ng, SH, et al. Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective phase II trial. Jpn J Clin Oncol 45 (2015), 819–827.
21. 21 Foo, KF, Tan, EH, Leong, SS, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 13 (2002), 150–156.
22. 22 Jiang, Y, Wei, YQ, Luo, F, et al. Gemcitabine and cisplatin in advanced nasopharyngeal carcinoma: a pilot study. Cancer Invest 23 (2005), 123–128.
23. 23 Zhang, L, Zhang, Y, Huang, PY, et al. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemother Pharmacol 61 (2008), 33–38.
24. 24 Chen, C, Wang, FH, Wang, ZQ, et al. Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol 48 (2012), 1146–1151.
25. 25 Wang, CC, Chang, JY, Liu, TW, Lin, CY, Yu, YC, Hong, RL, Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma. Head Neck 28 (2006), 74–80.
26. 26 Peng, P, Ou, X, Liao, H, et al. Phase II study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy. Ther Adv Med Oncol 8 (2016), 153–159.
27. 27 Ma, BB, Hui, EP, Wong, SC, et al. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma-correlation with excision repair cross-complementing-1 polymorphisms. Ann Oncol 20 (2009), 1854–1859.
28. 28 Chen, YP, Sun, Y, Chen, L, et al. Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: meta-analysis of randomised controlled trials. Radiother Oncol 116 (2015), 157–166.
29. 29 Hui, EP, Leung, SF, Au, JS, et al. Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer 101 (2004), 300–306.
30. 30 Pan, CC, Lu, J, Yu, JR, et al. Challenges in the modification of the M1 stage of the TNM staging system for nasopharyngeal carcinoma: a study of 1027 cases and review of the literature. Exp Ther Med 4 (2012), 334–338.